S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
Log in

TSE:TRL - Trilogy International Partners Stock Price, Forecast & News

C$1.70
-0.03 (-1.73 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
C$1.65
Now: C$1.70
C$1.77
50-Day Range
C$1.70
MA: C$1.88
C$2.05
52-Week Range
C$1.57
Now: C$1.70
C$3.45
Volume15,000 shs
Average Volume9,988 shs
Market CapitalizationC$98.64 million
P/E RatioN/A
Dividend Yield1.16%
BetaN/A
Trilogy International Partners Inc, together with its subsidiaries, provides wireless voice and data communication services in Bolivia and New Zealand. The company's communications services include local, international long distance, and roaming services for customers and international visitors roaming on their networks. It also provides fixed broadband communications services to business and residential customers. Read More…

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-425-4585900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$734.77 million
Cash FlowC$1.87 per share
Book ValueC($1.53) per share

Profitability

Miscellaneous

Employees1,821
Market CapC$98.64 million
Next Earnings Date3/25/2020 (Estimated)
OptionableNot Optionable

Receive TRL News and Ratings via Email

Sign-up to receive the latest news and ratings for TRL and its competitors with MarketBeat's FREE daily newsletter.


Trilogy International Partners (TSE:TRL) Frequently Asked Questions

What is Trilogy International Partners' stock symbol?

Trilogy International Partners trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRL."

How often does Trilogy International Partners pay dividends? What is the dividend yield for Trilogy International Partners?

Trilogy International Partners declared an annual dividend on Monday, April 15th. Shareholders of record on Monday, May 6th will be given a dividend of 0.02 per share on Monday, May 6th. This represents a yield of 0.86%. The ex-dividend date is Monday, April 15th. View Trilogy International Partners' Dividend History.

When is Trilogy International Partners' next earnings date?

Trilogy International Partners is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Trilogy International Partners.

What price target have analysts set for TRL?

2 analysts have issued 1-year price objectives for Trilogy International Partners' stock. Their forecasts range from C$3.25 to C$3.50. On average, they expect Trilogy International Partners' stock price to reach C$3.38 in the next twelve months. This suggests a possible upside of 98.5% from the stock's current price. View Analyst Price Targets for Trilogy International Partners.

What is the consensus analysts' recommendation for Trilogy International Partners?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trilogy International Partners in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trilogy International Partners.

Has Trilogy International Partners been receiving favorable news coverage?

Headlines about TRL stock have been trending very negative on Friday, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Trilogy International Partners earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Trilogy International Partners.

Who are some of Trilogy International Partners' key competitors?

What other stocks do shareholders of Trilogy International Partners own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trilogy International Partners investors own include Acerus Pharmaceuticals (ASP), Merck & Co., Inc. (MRK), Millicom International Cellular (MIICF), Oncolytics Biotech (ONCYF), Emera (EMA), Glacier Bancorp (GBCI), Fibrocell Science (FCSC), CytomX Therapeutics (CTMX), CSX (CSX) and Check Cap (CHEK).

Who are Trilogy International Partners' key executives?

Trilogy International Partners' management team includes the folowing people:
  • Mr. John William Stanton, Chairman (Age 64)
  • Mr. Bradley Jay Horwitz, Co-Founder, Pres, CEO & Non-Independent Director (Age 63)
  • Ms. Theresa E. Gillespie, Co-Founder & Non-Independent Director (Age 66)
  • Mr. Erik Mickels, Sr. VP & CFO
  • Mr. Scott Morris, Sr. VP, Gen. Counsel & Corp. Sec.

How do I buy shares of Trilogy International Partners?

Shares of TRL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Trilogy International Partners' stock price today?

One share of TRL stock can currently be purchased for approximately C$1.70.

How big of a company is Trilogy International Partners?

Trilogy International Partners has a market capitalization of C$98.64 million and generates C$734.77 million in revenue each year. Trilogy International Partners employs 1,821 workers across the globe.View Additional Information About Trilogy International Partners.

What is Trilogy International Partners' official website?

The official website for Trilogy International Partners is http://www.trilogy-international.co.../.

How can I contact Trilogy International Partners?

Trilogy International Partners' mailing address is Bellevue Wa PO Box 1988, BELLEVUE, WA 98009-1988, United States. The specialty pharmaceutical company can be reached via phone at +1-425-4585900.


MarketBeat Community Rating for Trilogy International Partners (TSE TRL)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  202 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  340
MarketBeat's community ratings are surveys of what our community members think about Trilogy International Partners and other stocks. Vote "Outperform" if you believe TRL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Featured Article: What are no-load funds?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel